Axsome Therapeutics has been granted a patent for compositions containing NSAIDs like meloxicam and rizatriptan with cyclodextrin or carbonate for improved bioavailability. The method involves orally administering the combination during a migraine attack for pain relief, well-tolerated with long-term use. GlobalData’s report on Axsome Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Axsome Therapeutics, Antibody-conjugate nanoparticles was a key innovation area identified from patents. Axsome Therapeutics's grant share as of May 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for treating migraine with meloxicam and rizatriptan
A recently granted patent (Publication Number: US11998552B2) discloses a method for treating migraines by orally administering a dosage form containing a combination of meloxicam and rizatriptan to migraine patients. The method involves administering the dosage form at least twice a month for a minimum of six months during a migraine attack, resulting in relief of migraine pain. The dosage form is well tolerated with long-term dosing and is particularly beneficial for migraine patients experiencing symptoms such as nausea, photophobia, or phonophobia.
Furthermore, the dosage form may also contain bicarbonate, SBEßCD, and specific amounts of meloxicam and rizatriptan to enhance its efficacy. The patent claims that the solid oral dosage form has a shorter Tmax of meloxicam compared to a reference dosage form, indicating faster relief for migraine patients. Additionally, the dosage form allows migraine patients to return to normal activities within 24 hours after receiving treatment. Overall, this patented method offers a promising approach to managing migraines effectively and improving the quality of life for migraine patients experiencing associated symptoms.
To know more about GlobalData’s detailed insights on Axsome Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
